Prevalence of migraine in Saudi Arabia and the efficacy of Eptinezumab: A pooled analysis and Meta-analysis from clinical trials
| dc.contributor.advisor | william miller | |
| dc.contributor.author | IBRAHIM SALMAN SALAH ALKHATTABI | |
| dc.date | 2021 | |
| dc.date.accessioned | 2022-06-04T19:35:01Z | |
| dc.date.available | 2022-05-30 22:58:27 | |
| dc.date.available | 2022-06-04T19:35:01Z | |
| dc.description.abstract | Eptinezumab 100 mg and 300 mg treated with intravenous over a 30-minute period on day 0 and week 12 showed prolonged migraine prevention effects. Eptinezumab has a high safety profile, despite expressing some minor side effects. Eptinezumab would be a promising treatment if it was approved in Saudi Arabia. | |
| dc.format.extent | 38 | |
| dc.identifier.other | 111168 | |
| dc.identifier.uri | https://drepo.sdl.edu.sa/handle/20.500.14154/66426 | |
| dc.language.iso | en | |
| dc.publisher | Saudi Digital Library | |
| dc.title | Prevalence of migraine in Saudi Arabia and the efficacy of Eptinezumab: A pooled analysis and Meta-analysis from clinical trials | |
| dc.type | Thesis | |
| sdl.degree.department | Clinical Pharmacology | |
| sdl.degree.grantor | UNIVERSITY OF GLASGOW | |
| sdl.thesis.level | Master | |
| sdl.thesis.source | SACM - United Kingdom |